Synopsys Forecast, price target & analysts
Synopsys Target price 2026 - Analyst rating & recommendation
Synopsys Classifications & Recommendation
Synopsys Price Target
| Target Price | $571.20 |
| Price | $425.76 |
| Potential | 34.16% |
| Number of Estimates | 28 |
| 28 Analysts have issued a price target Synopsys 2027 . The average Synopsys target price is $571.20. This is 34.16% higher than the current stock price. The highest price target is $664.65 56.11% , the lowest is $418.92 1.61% . | |
| A rating was issued by 32 analysts: 26 Analysts recommend Synopsys to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2027 of 34.16% . Most analysts recommend the Synopsys stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
29 Analysts have issued a sales forecast Synopsys 2026 . The average Synopsys sales estimate is
This results in the following potential growth metrics:
22 Analysts have issued an Synopsys EBITDA forecast 2026. The average Synopsys EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
30 Synopsys Analysts have issued a net profit forecast 2026. The average Synopsys net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
30 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is
This results in the following potential growth metrics and future valuations:
Current Synopsys Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Equal-Weight
➜
Overweight
|
Upgrade | Sep 10 2026 |
| Morgan Stanley |
Equal-Weight
➜
Overweight
|
Upgrade | Sep 08 2026 |
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Aug 27 2026 |
| Benchmark |
Buy
➜
Buy
|
Unchanged | Aug 27 2026 |
| Mizuho |
Outperform
➜
Outperform
|
Unchanged | Aug 27 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Aug 27 2026 |
| Baird |
Neutral
➜
Outperform
|
Upgrade | Aug 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Upgrade
Wells Fargo:
Equal-Weight
➜
Overweight
|
Sep 10 2026 |
|
Upgrade
Morgan Stanley:
Equal-Weight
➜
Overweight
|
Sep 08 2026 |
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Aug 27 2026 |
|
Unchanged
Benchmark:
Buy
➜
Buy
|
Aug 27 2026 |
|
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Aug 27 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Aug 27 2026 |
|
Upgrade
Baird:
Neutral
➜
Outperform
|
Aug 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
